Does the metabolic syndrome help to select patients requiring high statin dose?
Scheen
A J
AJ
Department of Medicine, CHU Sart Tilman (B35), B-4000 Liège, Belgium. andre.scheen@chu.ulg.ac.be
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D048909:Diabetes Complications; D004305:Dose-Response Relationship, Drug; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D024821:Metabolic Syndrome / Q000150:complications*; D018579:Patient Selection; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin